You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Quidel's preliminary earnings more than doubled over the prior quarter on increasing SARS-CoV-2 test sales.
The firm delivered record revenue and the most profitable quarter in its history as a result of the increased demand for its products.
Abcam will develop custom protein-based reagents for targets identified by researchers funded by Cancer Research UK.
Sema4 said it will provide SARS-CoV-2 viral and antibody testing to Connecticut residents including state employees and first responders.
The study aims to enroll 20,000 existing Biobank participants, as well as their adult children and grandchildren, from England, Scotland, and Wales.
The funding, provided by the Chan Zuckerberg Initiative, will help test and study the Bay Area population in general as well as healthcare workers in particular.
Healthy adults from across the US with no confirmed history of COVID-19 and no current symptoms are eligible to participate and will be enrolled over the phone.
The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.
Israel-based Best Medical Opinion and South Korea-based Dow Biomedica/Biodiscovery will distribute Oncimmune's EarlyCDTLung cancer test in those countries.
The firm is building an antibody-based immune system-related protein biomarker test for stroke diagnosis in both community and academic hospitals.
According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.
A number of United Nations agencies push for scientific findings to be made accessible through open science.
Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.
In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.